Ben Jones, technical manager, global serialisation services at PCI Pharma Services, discusses the complex world of serialisation and what strategies pharma companies can implement.
The United States drug market is comprised of a population of more than 330 million people. In terms of its attractiveness as a market for selling pharmaceutical therapies, it is valued at $358 billion annually and represents approximately 44% percent of the total global pharmaceutical market. Pharmaceutical companies operating in the United States are now expected to have taken initial steps in securing their supply chain, complying to the Drug Safety and Supply Chain Act (DSCSA) effective November of 2017. The US Food and Drug Administration provided a grace period, opting to defer enforcement of penalty for noncompliance until the fast approaching date of November 2018.